Securities class action litigation has been filed on behalf of investors who purchased or otherwise acquired the securities of Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS) between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”).

If you purchased or acquired Hims & Hers securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than August 25, 2025.

A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

Hims & Hers investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should complete the form below, text or email investorinfo@lchb.com, or call Lieff Cabraser partner Sharon M. Lee at 1-800-541-7358.

Hims & Hers is an American telehealth company incorporated in Delaware and headquartered in San Francisco, California. On April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk, centered around “a bundled offering of Novo Nordisk’s FDA-approved Wegovy® on the Hims & Hers platform.” Wegovy is a form of compounded semaglutide used for weight-loss.

The actions allege that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Hims & Hers was promoting and selling “illegitimate, knockoff versions of Wegovy” which endangered patients; and (2) as a result, there was a substantial risk that Hims & Hers’ recently announced partnership with Novo Nordisk would be terminated.

On June 23, 2025, Novo Nordisk announced that it was terminating its collaboration with the Company on account of Hims & Hers’ (1) “deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk” as the compounded semaglutide is manufactured by foreign suppliers in China not approved or regulated by the FDA, and may contain dangerous and illicit ingredients; and (2) failure to follow the law “prohibit[ing] mass sales of compounded drugs under the false guise of ‘personalization’.” On this news, the price of Hims & Hers common stock fell $22.24 per share, or 34.6%, from its closing price of $64.22 per share on June 20, 2025 to close at $41.98 per share on June 23, 2025.

Read our Securities and Investment Fraud Practice Area brochure